Novartis Total Assets from 2010 to 2025

NVS Stock

USD 112.13 1.08 0.95%

Novartis Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2000-06-30

Previous Quarter

103.5 B

Current Value

102.2 B

Quarterly Volatility

34.4 B

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 B, Interest Expense of 571.2 M or Selling General Administrative of 7.3 B, as well as many indicators such as Price To Sales Ratio of 2.76, Dividend Yield of 0.0247 or PTB Ratio of 2.35. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.

Check out the analysis of Novartis Correlation against competitors.

Latest Novartis' Total Assets Growth Pattern

Below is the plot of the Total Assets of Novartis AG ADR over the last few years. Total assets refers to the total amount of Novartis assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Novartis AG ADR books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Novartis' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 102.25 B

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Total Assets

Timeline

Novartis Total Assets Regression Statistics

	Arithmetic Mean	117,452,435,523
	Geometric Mean	113,775,032,595
	Coefficient Of Variation	20.50
	Mean Deviation	15,490,346,716
	Median	125,387,000,000
	Standard Deviation	24,081,243,537
	Sample Variance	579906290.3T
	Range	105.3B
	R-Value	0.12
	Mean Square Error	611654900T
	R-Squared	0.02
	Significance	0.65
	Slope	631,118,882
	Total Sum of Squares	8698594354T

Novartis Total Assets History

	2025	103.5 B
	2024	102.2 B
	2023	99.9 B
	2022	117.5 B
	2021	131.8 B
	2020	132.1 B
	2019	118.4 B

Other Fundumenentals of Novartis AG ADR

Intangibles To Total Assets

Novartis Total Assets component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Intangible Assets	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.91	0.52	0.66	0.92	0.92	0.74	-0.01	0.86	0.41	0.02	0.47	0.02	0.93	0.7	0.98	-0.1	0.84	0.14	0.37	0.3	-0.35	0.18	0.32	0.3	0.13
Total Stockholder Equity	0.91		0.63	0.35	0.97	0.81	0.7	-0.06	0.57	0.25	0.25	0.16	0.25	0.75	0.38	0.9	-0.36	0.87	0.47	0.24	0.45	-0.24	-0.17	0.22	0.52	0.27
Current Deferred Revenue	0.52	0.63		0.1	0.69	0.36	0.22	-0.26	0.25	0.04	0.12	-0.09	0.12	0.34	0.26	0.48	-0.28	0.46	0.47	0.22	0.48	-0.71	-0.15	0.05	0.31	0.12
Net Debt	0.66	0.35	0.1		0.43	0.58	0.55	0.11	0.87	0.22	-0.31	0.63	-0.31	0.83	0.91	0.65	0.22	0.35	-0.47	0.37	0.08	-0.3	0.65	0.23	-0.11	-0.16
Retained Earnings	0.92	0.97	0.69	0.43		0.82	0.72	-0.06	0.63	0.28	0.13	0.21	0.13	0.79	0.49	0.92	-0.26	0.87	0.41	0.3	0.39	-0.35	-0.08	0.23	0.42	0.26
Accounts Payable	0.92	0.81	0.36	0.58	0.82		0.67	-0.02	0.83	0.43	-0.06	0.43	-0.06	0.87	0.62	0.94	-0.07	0.85	0.01	0.18	0.12	-0.27	0.11	0.17	0.11	0.1
Net Receivables	0.74	0.7	0.22	0.55	0.72	0.67		-0.17	0.6	0.11	-0.02	0.35	-0.02	0.74	0.5	0.81	-0.22	0.79	0.18	0.28	0.19	0.06	0.1	0.16	0.2	0.01
Short Term Investments	-0.01	-0.06	-0.26	0.11	-0.06	-0.02	-0.17		0.06	0.67	-0.11	-0.08	-0.11	0.07	0.14	-0.04	0.2	-0.32	-0.16	0.06	-0.48	-0.02	0.23	0.28	0.01	0.77
Total Liab	0.86	0.57	0.25	0.87	0.63	0.83	0.6	0.06		0.49	-0.27	0.73	-0.27	0.91	0.92	0.84	0.23	0.58	-0.3	0.43	0.05	-0.39	0.56	0.36	-0.04	-0.07
Total Current Assets	0.41	0.25	0.04	0.22	0.28	0.43	0.11	0.67	0.49		-0.33	0.34	-0.33	0.36	0.47	0.36	0.34	0.11	-0.14	0.35	-0.51	-0.34	0.41	0.5	-0.1	0.55
Capital Stock	0.02	0.25	0.12	-0.31	0.13	-0.06	-0.02	-0.11	-0.27	-0.33		-0.35	1.0	-0.14	-0.43	-0.01	-0.79	0.1	0.74	-0.31	0.73	0.44	-0.74	-0.23	0.88	0.19
Short Term Debt	0.47	0.16	-0.09	0.63	0.21	0.43	0.35	-0.08	0.73	0.34	-0.35		-0.35	0.58	0.64	0.44	0.44	0.27	-0.41	0.58	-0.14	-0.08	0.6	0.45	-0.13	-0.38
Common Stock	0.02	0.25	0.12	-0.31	0.13	-0.06	-0.02	-0.11	-0.27	-0.33	1.0	-0.35		-0.14	-0.43	-0.01	-0.79	0.1	0.74	-0.31	0.73	0.44	-0.74	-0.23	0.88	0.19
Intangible Assets	0.93	0.75	0.34	0.83	0.79	0.87	0.74	0.07	0.91	0.36	-0.14	0.58	-0.14		0.81	0.93	0.05	0.69	-0.1	0.43	0.14	-0.31	0.33	0.31	0.12	0.09
Long Term Debt	0.7	0.38	0.26	0.91	0.49	0.62	0.5	0.14	0.92	0.47	-0.43	0.64	-0.43	0.81		0.67	0.37	0.35	-0.4	0.51	-0.03	-0.53	0.74	0.38	-0.19	-0.02
Good Will	0.98	0.9	0.48	0.65	0.92	0.94	0.81	-0.04	0.84	0.36	-0.01	0.44	-0.01	0.93	0.67		-0.15	0.88	0.14	0.31	0.24	-0.28	0.12	0.2	0.25	0.12
Treasury Stock	-0.1	-0.36	-0.28	0.22	-0.26	-0.07	-0.22	0.2	0.23	0.34	-0.79	0.44	-0.79	0.05	0.37	-0.15		-0.28	-0.66	0.38	-0.58	-0.26	0.73	0.38	-0.64	-0.12
Property Plant Equipment	0.84	0.87	0.46	0.35	0.87	0.85	0.79	-0.32	0.58	0.11	0.1	0.27	0.1	0.69	0.35	0.88	-0.28		0.31	0.07	0.34	-0.09	-0.13	0.04	0.28	-0.06
Net Tangible Assets	0.14	0.47	0.47	-0.47	0.41	0.01	0.18	-0.16	-0.3	-0.14	0.74	-0.41	0.74	-0.1	-0.4	0.14	-0.66	0.31		0.01	0.57	0.2	-0.73	0.01	0.81	0.41
Deferred Long Term Liab	0.37	0.24	0.22	0.37	0.3	0.18	0.28	0.06	0.43	0.35	-0.31	0.58	-0.31	0.43	0.51	0.31	0.38	0.07	0.01		-0.05	-0.27	0.5	0.79	0.04	0.06
Long Term Investments	0.3	0.45	0.48	0.08	0.39	0.12	0.19	-0.48	0.05	-0.51	0.73	-0.14	0.73	0.14	-0.03	0.24	-0.58	0.34	0.57	-0.05		0.04	-0.39	-0.11	0.72	-0.18
Short Long Term Debt	-0.35	-0.24	-0.71	-0.3	-0.35	-0.27	0.06	-0.02	-0.39	-0.34	0.44	-0.08	0.44	-0.31	-0.53	-0.28	-0.26	-0.09	0.2	-0.27	0.04		-0.39	-0.17	0.31	-0.05
Long Term Debt Total	0.18	-0.17	-0.15	0.65	-0.08	0.11	0.1	0.23	0.56	0.41	-0.74	0.6	-0.74	0.33	0.74	0.12	0.73	-0.13	-0.73	0.5	-0.39	-0.39		0.47	-0.54	-0.21
Cash And Equivalents	0.32	0.22	0.05	0.23	0.23	0.17	0.16	0.28	0.36	0.5	-0.23	0.45	-0.23	0.31	0.38	0.2	0.38	0.04	0.01	0.79	-0.11	-0.17	0.47		0.06	0.24
Net Invested Capital	0.3	0.52	0.31	-0.11	0.42	0.11	0.2	0.01	-0.04	-0.1	0.88	-0.13	0.88	0.12	-0.19	0.25	-0.64	0.28	0.81	0.04	0.72	0.31	-0.54	0.06		0.33
Net Working Capital	0.13	0.27	0.12	-0.16	0.26	0.1	0.01	0.77	-0.07	0.55	0.19	-0.38	0.19	0.09	-0.02	0.12	-0.12	-0.06	0.41	0.06	-0.18	-0.05	-0.21	0.24	0.33

Click cells to compare fundamentals

About Novartis Financial Statements

Novartis shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Novartis investors may analyze each financial statement separately, they are all interrelated. The changes in Novartis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Novartis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Total Assets	102.2 B	103.5 B
Intangibles To Total Assets	0.51	0.27

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC